Skip to main content

3 Result(s)

within Shu-Feng Zhou Remove this filter Oncology Remove this filter

and

  1. Article

    Open Access

    Proteomics reveals a therapeutic vulnerability via the combined blockade of APE1 and autophagy in lung cancer A549 cells

    Drug resistance is a major cause of therapeutic failure that is often associated with elevated autophagy and apurinic/apyrimidinic endonuclease 1 (APE1) expression. Herein, we investigated the role of APE1 and...

    Shu-Ting Pan, Ji Zhou, Fang Yang, Shu-Feng Zhou, Tao Ren in BMC Cancer (2020)

    Download PDF (2772 KB) View Article

  2. No Access

    Chapter

    Toxicology, Safety and Herb–drug Interactions in Cancer Therapy

    Cancer patients always seek alternative approaches without advising the oncologists about their use of herbal/dietary supplements. There are increased reports on the interaction of herbal medicines and antican...

    Shu-Feng Zhou in Supportive Cancer Care with Chinese Medicine (2010)

  3. No Access

    Article

    Biotransformation and pharmacokinetics of the novel anticancer drug, SYUIQ-5, in the rat

    SYUIQ-5, a novel telomerase inhibitor, has demonstrated antitumor activity in nude mouse studies. The objective of the present study was to examine the metabolism and pharmacokinetics of SYUIQ-5 in rats. The p...

    Qi-Biao Su, Fan He, Xue-Ding Wang, Su Guan, Zhi-Yong **e… in Investigational New Drugs (2008)